SCHEMBL11453067

SCHEMBL11453067

CCn1c2ccc(Cl)cc2c2cc(C=O)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 5/20 1.00
MAPT P10636 5/20 0.48
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 4/20 0.48
HPGD P15428 3/20 0.48
HSD17B10 Q99714 3/20 0.48
MAPK1 P28482 2/20 0.48
LMNA P02545 2/20 0.48
HTT P42858 2/20 0.47
POLB P06746 1/20 0.47
PKM P14618 1/20 0.47
PLK1 P53350 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SRC P12931 2/20 0.45
TP53 P04637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4832600 0.90 PTGER4 (0.81) PTGER4MAPTKDM4EALDH1A1HPGD
SCHEMBL29794143 0.90 PTGER4 (0.81) PTGER4MAPTKDM4EALDH1A1HPGD
SCHEMBL1921261 0.85 PTGER4 (0.72) PTGER4MAPTKDM4EALDH1A1HPGD
SCHEMBL29507657 0.83 PTGER4 (0.70) PTGER4MAPTKDM4EALDH1A1HPGD
SCHEMBL15774538 0.83 PTGER4 (0.70) PTGER4MAPTKDM4EALDH1A1HPGD
SCHEMBL416844 0.83 PTGER4 (0.70) PTGER4MAPTKDM4EALDH1A1HPGD
SCHEMBL16066019 0.81 PTGER4 (0.68) PTGER4MAPTKDM4EALDH1A1HPGD
SCHEMBL31021119 0.81 PTGER4 (0.68) PTGER4MAPTKDM4EALDH1A1HPGD
SCHEMBL28413514 0.81 PTGER4 (0.68) PTGER4MAPTKDM4EALDH1A1HPGD
SCHEMBL30061939 0.81 PTGER4 (0.68) PTGER4MAPTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113024691-B Low-migration carbazolyl acylphosphine photoinitiator and synthesis method thereof 华南理工大学 2022-05-24 CN disclosed
CN-113024691-A Low-migration carbazolyl acylphosphine photoinitiator and synthesis method thereof 华南理工大学 2021-06-25 CN disclosed
US-9708311-B2 Benzimidazole derivatives as EP4 antagonists BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-07-18 US disclosed
US-9708311-B2 Benzimidazole derivatives as EP4 antagonists BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-07-18 US disclosed
US-9708311-B2 Benzimidazole derivatives as EP4 antagonists BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-07-18 US disclosed
EP-2928884-B1 NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS Bayer Pharma AG (DE) 2017-05-24 EP disclosed
US-20160214977-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS BAYER ANIMAL HEALTH GMBH (DE) 2016-07-28 US disclosed
US-20160214977-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS BAYER ANIMAL HEALTH GMBH (DE) 2016-07-28 US disclosed
EP-2928884-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS Bayer Pharma Aktiengesellschaft (DE) 2015-10-14 EP disclosed
CN-104854098-A NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS Bayer Pharma AG 2015-08-19 CN disclosed
WO-2014086739-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-06-12 WO disclosed
US-4202820-A Pressure-sensitive or heat-sensitive recording material containing a carbazolyl methane compound CIBA-GEIGY CORPORATION (US) 1980-05-13 US disclosed
US-4154463-A Pressure-sensitive or heat-sensitive recording material containing a carbazolyl methane compound CIBA-GEIGY CORPORATION (US) 1979-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214977-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS PTGER4, PTGER1, PTGER2 PTGER4 1/4885MAPT 4657/4885KDM4E 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.